KT6 971

Drug Profile

KT6 971

Alternative Names: KT6-971; S-556971

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kotobuki Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol absorption inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias

Most Recent Events

  • 21 Aug 2015 Phase-II development is ongoing in Japan
  • 21 Aug 2015 KT6 971 is no longer licensed to Shionogi in World
  • 07 Feb 2013 Shionogi initiates a Phase-IIb trial for Dyslipidaemias in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top